Current Headlines

  1. Boehringer Ingelheim, CureVac Partner On Lung Cancer Immunotherapy
    9/23/2014

    Boehringer Ingelheim has obtained exclusive rights to develop and market CureVac’s investigational lung cancer immunotherapy. Announced in a press release, the new partnership will focus on the CV9202 vaccine based on CureVac’s mRNA technology (RNActive).

  2. U.S. Government Takes Steps To Combat Antibiotic Resistance
    9/23/2014

    The U.S. government initiated a new strategy last week to track trends in antibiotic resistance, due to reports that it is the cause for at least 23,000 deaths and two million illnesses each year.  The plan lays out specific steps to prevent this epidemic and to accelerate the research and development of new antibiotics by 2020.

  3. Lilly Posts Positive Trial Results For Cyramza In Gastric Cancer
    9/22/2014

    Eli Lilly & Co. announced positive results from the global Phase 3 trial of Cyramza (ramucirumab) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma.

  4. Bayer To Focus On Life Sciences, Splits Off MaterialScience Business
    9/22/2014

    Bayer announced it plans to devote its full attention to its Life Science businesses, which includes HealthCare and CropScience, and to float its MaterialScience plastics business on the stock market in 2016 as a separate entity.

  5. Relmada And MSKCC Partner In Opioid Painkiller Studies
    9/22/2014

    Clinical stage firm Relmada Therapeutics announced that it has partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to launch several animal studies of levorphanol for chronic pain.

  6. Epirus’s Biosimilar Arthritis Drug Wins Approval In India
    9/22/2014

    Boston-based biotech firm, Epirus Biopharmaceuticals, has received final marketing and manufacturing approvals from India’s drug regulators for its Remicade (infliximab) biosimilar, BOW015, making it the first infliximab biosimilar approved in India.

  7. Dyzle To Demonstrate Integrated Monitoring, Tracking And Analytics Platform Complete With Mobile App To Enable Full Cold Chain Visibility Worldwide And Deliver Proof Of Product Integrity
    9/22/2014

    Dyzle BV, the global leader in measuring and analyzing business process data for the cold chain in real-time, will demonstrate a complete technology platform solution to enable full cold chain visibility worldwide and provide proof of product integrity at the 12th Annual Cold Chain GDP & Temperature Management Logistics Global Forum in Boston, MA, USA next week (1-2 October 2014).

  8. New Chronic Lymphocytic Leukemia Therapy Enters Phase 1 Trial`
    9/19/2014

    Researchers at the University of California, San Diego School of Medicine have just moved their novel monoclonal antibody called cirmtuzumab (UC-961) into a phase 1 human clinical trial for treating chronic lymphocytic leukemia (CLL).

  9. Puerto Rico To Be New Hub For HIV Vaccine R&D
    9/19/2014

    Puerto Rico is set to become the center of research and development activities for HIV/AIDS, thanks to a multi-stakeholder collaboration that will be attempting to produce a prophylactic vaccine against the infection.

  10. Pfizer, MedGenesis’ Team Up To Explore Potential Parkinson’s Treatments
    9/19/2014

    Biotech firm MedGenesis Therapeutix announced that it has agreed to grant Pfizer an exclusive, global option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology for research as treatment for Parkinson's disease.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.